한글목차

약제 요약

Remibrutinib(LOU064)는 B세포와 미세아교세포 등 특정 면역세포의 염증 활성에 중요한 역할을 하는 브루톤형 티로신 키나아제(BTK) 효소를 강력하고 선택적으로 억제하는 경구용 치료제입니다. Remibrutinib은 비만세포와 호염기구의 IgE 가교에 의해 유발되는 탈과립과 특발성 및 유발성 만성 두드러기 환자의 혈청에 존재하는 인자에 의해 유발되는 활성화를 억제합니다.

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 만성 특발성 두드러기(CSU)용 Remibrutinib에 대해 조사분석했으며, 시장 규모 예측 및 작용기서, 용법과 용량, 연구개발 활동 등의 정보를 제공하고 있습니다.

목차

제1장 리포트 서론

제2장 만성 특발성 두드러기(CSU)에서 Remibrutinib의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품의 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 치료법)

제5장 Remibrutinib 시장 평가

• 만성 특발성 두드러기(CSU)에서 Remibrutinib 시장 전망
• 주요 7 시장의 분석
  • 주요 7 시장의 만성 특발성 두드러기(CSU)용 Remibrutinib 시장 규모
• 시장의 분석 : 국가별
  • 미국의 만성 특발성 두드러기(CSU)용 Remibrutinib 시장 규모
  • 독일의 만성 특발성 두드러기(CSU)용 Remibrutinib 시장 규모
  • 영국의 만성 특발성 두드러기(CSU)용 Remibrutinib 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"Remibrutinib Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Remibrutinib for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the Remibrutinib for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Remibrutinib for CSU. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Remibrutinib market forecast analysis for CSU in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.

Drug Summary:

Remibrutinib (LOU064) is an oral treatment that potently and selectively inhibits Bruton's tyrosine kinase (BTK) enzyme, which plays a critical role in the inflammatory activity of certain immune cells such as B cells and microglia. Remibrutinib inhibits degranulation induced by IgE cross-linking in mast cells and basophils and the activation triggered by factors present in the sera of spontaneous and inducible chronic urticaria patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Remibrutinib description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
• Elaborated details on Remibrutinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Remibrutinib research and development activities in CSU across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Remibrutinib.
• The report contains forecasted sales of Remibrutinib for CSU till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CSU.
• The report also features the SWOT analysis with analyst views for Remibrutinib in CSU.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Remibrutinib Analytical Perspective by DelveInsight

• In-depth Remibrutinib Market Assessment

This report provides a detailed market assessment of Remibrutinib for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Remibrutinib Clinical Assessment

The report provides the clinical trials information of Remibrutinib for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Remibrutinib dominance.
• Other emerging products for CSU are expected to give tough market competition to Remibrutinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Remibrutinib in CSU.
• Our in-depth analysis of the forecasted sales data of Remibrutinib from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Remibrutinib in CSU.

Key Questions:

• What is the product type, route of administration and mechanism of action of Remibrutinib?
• What is the clinical trial status of the study related to Remibrutinib in Chronic Spontaneous Urticaria (CSU) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Remibrutinib development?
• What are the key designations that have been granted to Remibrutinib for CSU?
• What is the forecasted market scenario of Remibrutinib for CSU?
• What are the forecasted sales of Remibrutinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Remibrutinib for CSU?
• Which are the late-stage emerging therapies under development for the treatment of CSU?

Table of Contents

1. Report Introduction

2. Remibrutinib Overview in Chronic Spontaneous Urticaria (CSU)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Remibrutinib Market Assessment

• 5.1. Market Outlook of Remibrutinib in Chronic Spontaneous Urticaria (CSU)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Remibrutinib in the 7MM for Chronic Spontaneous Urticaria (CSU)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Remibrutinib in the United States for Chronic Spontaneous Urticaria (CSU)
  • 5.3.2. Market Size of Remibrutinib in Germany for Chronic Spontaneous Urticaria (CSU)
  • 5.3.3. Market Size of Remibrutinib in France for Chronic Spontaneous Urticaria (CSU)
  • 5.3.4. Market Size of Remibrutinib in Italy for Chronic Spontaneous Urticaria (CSU)
  • 5.3.5. Market Size of Remibrutinib in Spain for Chronic Spontaneous Urticaria (CSU)
  • 5.3.6. Market Size of Remibrutinib in the United Kingdom for Chronic Spontaneous Urticaria (CSU)
  • 5.3.7. Market Size of Remibrutinib in Japan for Chronic Spontaneous Urticaria (CSU)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options